InMed Pharmaceuticals Inc (INM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is deteriorating, technical indicators are bearish, and there are no significant positive catalysts or trading signals to suggest a strong entry point.

Technical Analysis

The MACD is slightly positive and expanding, but the RSI is neutral at 41.758, showing no clear momentum. The moving averages are bearish, with SMA_200 > SMA_20 > SMA_5. The stock is trading near its pivot level of 0.896, with resistance at 0.942 and support at 0.85. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

The company's financials are deteriorating significantly, with revenue, net income, EPS, and gross margin all showing sharp declines in the latest quarter (2026/Q2). There is no recent news or trading activity to offset these negatives.

Financial Performance

In 2026/Q2, revenue dropped by -26.22% YoY to $820,188. Net income fell by -21.23% YoY to -$2,028,223. EPS plummeted by -85.99% YoY to -0.51, and gross margin dropped by -49.65% YoY to 15.97%. These metrics indicate a significant decline in financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast INM stock price to rise

Buy

Hold

Sell

Current: 0.850

Low

Averages

High